2753-45-9
2753-45-9
Chemical Structure
Mebeverine hydrochloride
- CAS No.: 2753-45-9
- Formula:C25H36ClNO5
- Molecular Weight:466.01
IUPAC Name: 4-(ethyl(1-(4-methoxyphenyl)propan-2-yl)amino)butyl 3,4-dimethoxybenzoate hydrochloride
InChIKey: PLGQWYOULXPJRE-UHFFFAOYSA-N
SMILES: O=C(OCCCCN(CC)C(C)CC1=CC=C(OC)C=C1)C2=CC=C(OC)C(OC)=C2.[H]Cl
Biological Activity: Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Mebeverine hydrochloride | 99.85% | Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mebeverine hydrochloride (Standard) | ≥98% | Mebeverine (hydrochloride) (Standard) is the analytical standard of Mebeverine (hydrochloride). This product is intended for research and analytical applications. Mebeverine hydrochloride, a β-phenylethylamine derivative, is a musculotropic agent that potently blocks intestinal peristalsis. Mebeverine directly blocks voltage-operated sodium channels and inhibits intracellular calcium accumulation. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Mebeverine-d6 hydrochloride | 0 | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Annaházi A, et al. Role of antispasmodics in the treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20(20):6031-6043. [Content Brief]
- [2]. Den Hertog A, et al. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol. 1987 Jun 26;138(3):367-74. [Content Brief]
